Skip to content
Screener

Novavax NVAX Transition Services — Cumulative catch up adjustment

Similar metrics at other companies

SoundThinking, Inc. logo
SSTICatch Up — Revenue
$100K-97.1%
InterDigital logo
IDCCCatch-up revenue — Revenue
$103.75M-36.1%
Textron logo
TXTBell — Expected unfavorable catch-up program adjustment
$120M
SoundThinking, Inc. logo
SSTICatch Up — Number Of Contract
2
Accenture logo
ACNCumulative translation adjustment
$856.25K-74.5%
Marathon Digital Holdings logo
MARACumulative translation adjustment
-$1.65M

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+0.5%
Enterprise value$1.38B+27.9%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract.

The source filing: Novavax’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001000694-26-000018

The Sanofi Transition Services and Sanofi Technology Transfer are recognized in revenue over time using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. Revenue recognized related to Sanofi Transition Services and Sanofi Technology Transfer for the three and six month period ended June 30, 2026 was $35.1 million and $80.5 million, respectively. Revenue recognized related to Sanofi Transition Services and Sanofi Technology Transfer for the three and six month period ended June 30, 2025 was $24.4 million and $64.7 million, respectively. The Company’s consolidated balance sheet as of June 30, 2026 includes an unbilled revenue balance of $0.9 million related to Sanofi Transition Services and Sanofi Technology Transfer. The Company recognized a cumulative catch-up adjustment related to changes in estimates, which resulted in an increase to revenue of $10.8 million and $15.4 million for the three and six month periods ended June 30, 2026, respectively. These changes in estimates resulted from changes in total expected costs and changes to estimates of variable consideration from expected cost reimbursements.

Item 1. Consolidated Financial Statements

FAQ

What is Novavax's transition services — cumulative catch up adjustment?
Novavax (NVAX) reported transition services — cumulative catch up adjustment of $10.8M in Q2 2026.
How has Novavax's transition services — cumulative catch up adjustment changed year-over-year?
Novavax's transition services — cumulative catch up adjustment increased by 820.0% year-over-year, from -$1.5M to $10.8M.
What does transition services — cumulative catch up adjustment mean?
This adjustment reflects the impact of changes in transaction price estimates or contract modifications on revenue recognized in prior periods for the transition services segment. It is used to align the cumulative revenue recognized to date with the updated expectations of total consideration. Significant adjustments may indicate volatility in contract performance or changes in underlying commercial assumptions.

Ask your AI about Novavax's transition services — cumulative catch up adjustment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude